ZEAL — Zealand Pharma A/S Share News
0.000.00%
Last trade - 00:00- DKK20.13bn
- DKK6.08bn
- DKK9.21bn
Danish biotech firm Zealand Pharma proposes former Novo Nordisk senior to board
Brief: Zealand Pharma, Roche To Advance petrelintide To Phase 3 Trials For Chronic Weight Management
Zealand rises as survodutide shows over 16% weight loss
Boehringer-Zealand drug leads to 16.6% weight loss in late-stage trial (updated)
Brief: Zealand Pharma Says Study In Glucagon/GLP-1 Dual Agonist Survodutide Met Primary Endpoints
Boehringer-Zealand drug leads to 16.6% weight loss in late-stage trial
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Zealand Pharma slump wipes billions off its value after obesity drug data disappoints (updated)
Zealand Pharma slump wipes billions off company value after obesity drug data disappoints
Zealand Pharma tracks worst day ever as obesity drug trial results disappoint
Swiss stocks - Factors to watch on March 6
Brief: Zealand Pharma Announces Positive Phase 2 Results For Petrelintide
Novo Nordisk's $475-billion rise and fall as Wegovy-era gains wiped out (updated)
Novo Nordisk slump wipes out last Wegovy-era gains after trial setback
Novo Nordisk slumps to almost 5-yr lows after obesity drug trial disappoints investors
Brief: Zealand Pharma Fy Revenue Up At DKK 9,215 Million
Brief: Zealand Pharma Announces Positive Phase 1A Topline Results With Kv1.3 Channel Blocker Zp9830
European shares edge higher, buoyed by financials (updated)